Home > Dermatology > PFGC 2021 > Psoriasis Therapy: New Findings > IL-36 gene expression in GPP lesions reduced by spesolimab

IL-36 gene expression in GPP lesions reduced by spesolimab

Presented By
Dr Ahmed Farag
PFGC 2021
Different patterns of gene expression were identified in lesional compared with non-lesional skin of patients with generalised pustular psoriasis (GPP). In the Effisayil 1 trial, various changes present in lesional skin were re-transformed after spesolimab treatment. “It is known that the dysregulation of the IL-36 signalling pathway is involved in the GPP pathogenesis,” Dr Ahmed Farag (Boehringer Ingelheim, Germany) stated. Spesolimab is a monoclonal, anti-IL-36R antibody with proven efficacy as a treatment of flaring GPP in the phase 2 Effisayil 1 trial (NCT03782792) [1,2]. This study also included a gene analysis of skin biopsies taken from lesional and non-lesional sites at different time points. The study comprised 53 GPP patients experiencing an acute flare, who were randomised 2:1 to receive 900 mg of spesolimab or placebo once [2]. The primary endpoi...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on